Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NY\oUY9kTnWwY4Tpc44hSXO|YYm= M{XwZlIh|ryP NYDYSG1IOSCq MoXLbY5pcWKrdIOgeIhmKExvRF;QRUApOjEEoN88UUkucW6mdXPl[EB1emGwc3nlcpQhTVKNMT:yJJBpd3OyaH;yfYxifGmxbtMg MUmyOlM3OzF7MR?=
C2C12 M{i1RmZ2dmO2aX;uJGF{e2G7 MkK4NeKh|rypL33s NV;m[VVrOcLiaB?= MWnhZo9tcXOqZYOgZ5l1d2urbnWgdoVt\WG|ZTDmdo9uKEN{Q{GyJI16d3S3YnXz MWiyOlI6OTJ5OR?=
MEFs WT MVvGeY5kfGmxbjDBd5NigQ>? MU[1xsDPxE1? NU\NNJpQOjBibXnu NUjp[m9b[2G3c3XzJJJme2mmZX70JIVvgnmvZYOgd5VkcCCjczDORWdVNUeIUDygeI8h\GmoZoXz[UBj[WOtIITvJJRp\SCHUh?= M1;WXVI3OTl4MEKz
MEFs VAMP7 KO MWnGeY5kfGmxbjDBd5NigQ>? M{fq[FXDqM7:TR?= MmraNlAhdWmw NHHIWmFk[XW|ZYOgdoV{cWSnboSg[Y57gW2nczDzeYNpKGG|IF7BS3QuT0[SLDD0c{BlcW[odYPlJIJi[2tidH:geIhmKEWU NH;jZoEzPjF7NkCyNy=>
SMCs MV;GeY5kfGmxbjDBd5NigQ>? NFKzcpAyOMLiwsXnM41t MUiwMVEzKGh? M1HObmROW09? MXrzbI94eyCjIITy[Y5lKHSxd3Hy[JMh[SCqaXfo[ZIh[2:wY3XueJJifGmxbjDv[kB1cGViRWKvV3IhdmW2d3;yb{BqdiC2aHWgdIVzcW63Y3zlZZIh[XKnYdMg NHnOWZczPjF5MkC4NC=>
SMCs M2jH[WZ2dmO2aX;uJGF{e2G7 MmrMNVDDqML3Zz;tcC=> NVr2XXQ2OC1zMjDo MYrEUXNQ MV\jZZV{\XNiYTD0doFve2mnboSgR4EzM8LicnXs[YF{\SCocn;tJJRp\SCHUj;TVuKh MXeyOlE4OjB6MB?=
HEMC-1 NG[3enNHfW6ldHnvckBCe3OjeR?= NYDUTlhlOC5zwrFCuYcwdWx? MXSyOOKhcA>? MnrSZ4F2e2W|IHGgbIlocGW{IHnubIljcXSxcomg[YZn\WO2IH;uJIV5d2O7dH;zbZMhfGijbjDuc4Nw\GG8b3zl MnHiNlU6PzJ5NUm=
HUVEC NVu3fJNCTnWwY4Tpc44hSXO|YYm= MXqxNOKh|ryP M2LFVFHDqGh? M1nrV2ROW09? MlXDZYJwdGm|aHXzJIh6eG:6aXGtbY5lfWOnZDDy[Yxm[XOnIH;mJGFVWCCocn;tJIFxcWOjbDDhcoQh[mG|b3zheIVz[Wxic4Xy[oFk\XN? M1n4dFI2QTV4OUi4
HUVEC NYqxZ3I4TnWwY4Tpc44hSXO|YYm= Mo\BNVDDqM7:TR?= M3\WWVHDqGh? NWWxN5ZjTE2VTx?= M1L0R4lv[3KnYYPld:KhfGinIH71cYJmeiCjbnSgbY51\W6|aYT5JI9nKG[udX;y[ZNk\W62IHHy[YF{KGW|cHXjbYFtdHliaX6gdIVzcW63Y3zlZZIhe3CjY3W= NWTXeXZFOjV7NU[5PFg>
Caco-2 MkPtSpVv[3Srb36gRZN{[Xl? MoXwNk42KM7:TR?= M2LOR|MxKG2rbh?= NWrZd4tH[XS2ZX71ZZRmeyC2aHWgWGdHNc7{MT3t[YRq[XSnZDDpcoNz\WG|ZTDpckBUTVKWIH\1coN1cW:w MlTBNlU6PTR7M{G=
NRK M{S2cGZ2dmO2aX;uJGF{e2G7 NUGwXpFJOjBy4pEFcocwdWx? Ml3ZOQKBjWh? M3XHWWROW09? MXry[ZNkfWW|IH3peI91cWNicILv[5Jme3Orb36= MW[yOVk1QDV6Nh?=
HeLa MXTGeY5kfGmxbjDBd5NigQ>? MXGyNFDjiIWwZz;tcC=> MlTsN{Bp NXq3[lZ2TE2VTx?= NYfTbXdxcW6mdXPld{B1cGViYYL0bYZq[2mjbDDidoVicy23cDDv[kB1cGViR3;s[4kh[2:vcHzlfC=> NYOzRXZPOjV7NEi1PFY>
COS M3P4WWZ2dmO2aX;uJGF{e2G7 MYOxJO69\y:vbB?= MoO5N{Bp NIXodmdkd22ybHX0[Yx6KGSrc4DldpNmeyC2aHWgRXAuOSC|aXfuZYzDqA>? M4XXWFI2QTF3OUCw
DF1  NEj2TmpHfW6ldHnvckBCe3OjeR?= NG\6ZmoyyqEQvF5CpC=> NX3ybnlKPDhiaB?= NIfOe3JFVVOR NUP2dGZo\Gm|cHXyd4V{yqC2aHWg[Zhw\2Wwb4XzJGNUT2GuTlHjWFIheHKxdHXpci=> M2C2SlI2QDB5MEW0
nHDFs  NGm0dlZHfW6ldHnvckBCe3OjeR?= NH7s[20yyqEQvF5CpC=> MV:yxsBp NVnQSI93eHKndnXueJMhfGinIHHzd4Vu[my7IH;mJIN6fG:|b3zpZ{Bkd2G2IIDyc5RmcW6|IH;ueI8hT2:uZ3mgcYVu[nKjbnXz NXTRO|lQOjV5N{K2NVY>
FRT  NELnSmxHfW6ldHnvckBCe3OjeR?= MkDaOUDPxGdxbXy= MVOyxsBp NXjH[mZl[myxY3vzJJRz[W[oaXPrbY5oKHSqcn;1[4ghfGinIFfvcIdqKGOxbYDs[Zgh[nliaX7obYJqfGmwZzDFVk11dy2Jb3znbUB1emGwc4DvdpQ> MoPDNlU4PjdzMUW=
FRT  NVvXboRnTnWwY4Tpc44hSXO|YYm= MUG1JO69\y:vbB?= M2TBWVLDqGh? Ml3tdJJmfmWwdIOgeIhmKGmwY4LlZZNmKGmwIHPs[YF3\WRizsGgd5VjfW6rdIOge4hmdiCdTnGrYYnDqHejczDy[YR2[2Wm NGnSeFkzPTd4N{GxOS=>
HepG2  NEDYTZdHfW6ldHnvckBCe3OjeR?= MnnXNgKBkcL3TdMg NFrSTY0zPCCq M1jLVGROW09? NXfHSm44\GWlcnXhd4V{KHSqZTDs[ZZmdCCxZjDQXHIhdVKQQR?= NVXhWG44OjV4MU[1PVc>
SMCs MmTlSpVv[3Srb36gRZN{[Xl? M2TPZVHPxGdxbVy= NX:2fZFlOyCq NYfDUFBT[WOldX31cIF1\XNiQ17QXVIheHKxdHXpckBqdiC2aHWgSXIh[2:vcHHyeI1mdnRiYX7kJI5wKGyxbnfldkBkdy2ub3PhcIl7\WRid3n0bEB1cGViR3;s[4khdWG{a3XyxsA> NFTNTlEzPTV6OUSyOS=>
OB-6 MnO3RZBweHSxc3nzJGF{e2G7 M2PzPFIvP8LizszN NFnORlI1QCCq MX\pcoR2[2W|IHHwc5B1d3Orcx?= NXr2dm9oOjV3M{K0PFA>
iPSC-CMs  MkjUSpVv[3Srb36gRZN{[Xl? NYDRN41xPTByIH7nM41t MWG0PEBp NHvVU4hqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kB1cGViaHnnbIVzKG2xYnnsbZR6KEyDTWDzJIF1KHSqZTDjc5N1KG:oIITo[UBtd3encjDtc4JqdGm2eTDzdIVkcWW| MXOyOVQ5QDZ4Nh?=
SP-Nluc Mmr3SpVv[3Srb36gRZN{[Xl? NITmdok2KG2pL33M NVj3eYUzPiCq MVHEUXNQyqB? M4LW[YNifXOnczDhckBqdmO{ZXHz[UBqdiC{ZYDvdpRmeiCjY4Tpeol1gSCrbjD0bIUheGG{YYPpeIU> M{\6SVI2Ozl{OUm4
PEXEL-Nluc NYXJbWF5TnWwY4Tpc44hSXO|YYm= MX:1JI1oN22O MWG2JIg> NEL0XGFFVVORwrC= NGe0NVBk[XW|ZYOgZY4hcW6lcnXhd4UhcW5icnXwc5J1\XJiYXP0bZZqfHliaX6geIhmKHCjcnHzbZRm NV7wUVdkOjV|OUK5PVg>
H1299 MYDGeY5kfGmxbjDBd5NigQ>? MnfINVAh|rypL33s M3;uOVI1KGh? M4TmRolv\HWlZYOgZZV1d3CqYXf5xsA> NVnRelhsOjV|OEi5O|A>
MDA-MB-231 M3ztXWNmdGxiVnnhZoltcXS7IFHzd4F6 Mk\vNQKBmzVyIN88[{9uVA>? M4L6[FQ5KGh? Mn6zSWM2OMLiPTCwMlAyPiEEtXevcWw> MmfKNlU{PTZ3Nke=
MDA-MB-231 Mn33RZBweHSxc3nzJGF{e2G7 MnzRNE4yKM7:Zz;tUC=> NXKycJdVPCCq M2ja[Ilv\HWlZYOgZZBweHSxc3nz MYWyOVM2PjV4Nx?=
MDA-MB-231 NF7h[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCwMlAyNzBwMEWg{txoN22O MU[yOEBp M3nLWolv[3KnYYPld{B1cGViZoLhZ5Rqd25ib3[gd5VjNUdzIHPlcIwh\GWkcnnz M3fJTlI2OzV4NU[3
MDA-MB-231 NVXnSIxJSXCxcITvd4l{KEG|c3H5 MWGwMlA26oDVMTFOwIcwdUx? MmrTNlQhcA>? NUnpZYJzcW6mdXPld{BRSVKSIDjwc4x6KEGGUD3ybYJwe2VicH;sfY1memG|ZT2xLUBkdGWjdnHn[S=> Mn\sNlU{PTZ3Nke=
MDA-MB-231 NUm5RoZtTnWwY4Tpc44hSXO|YYm= NGj5U20x6oDVNUCg{txoN22O M2TkZVI1KGh? MU\pcohq[mm2czD0bIUh\m:{bXH0bY9vKG:oIEPEJIFv\CB{RDDjc4xwdmmncx?= MlHNNlU{PTZ3Nke=
A172 NV;nUWg2TnWwY4Tpc44hSXO|YYm= Mof3NVDDqM7:Zz;tcC=> MlfQOOKhcA>? NXWwVHNnTE2VT9Mg MnHxdoV{fWy2czDpckB1cGVicnX0do9oemGmZTD0doFve3CxcoSgc4Yh\my3b4Lld4NmdnRiZ4LhcpVt\XN? M2r6PVI2OjN7NUC3
KMS-6 NXrwWnRiTnWwY4Tpc44hSXO|YYm= NEPJXJEyyqEQvF5CpC=> MlzZNlQhcA>? NIXobFlmgGirYnn0d{Bp[WyoIITo[UB{\WO{ZYTpc44hd2ZiZ3HsZY5qdi2OSTDhd{BlcWRidHjlJINwdnS{b3y= M3fmdVI2OjJ7MUK2
MEC MX;GeY5kfGmxbjDBd5NigQ>? NE[xZWwyKM7:TR?= MX6xMlUhcA>? MXzjZZV{\XNiYTDkdoFu[XSrYzDk[YNz\WG|ZTDpckB1cGVic4Xy[oFk\SCYRVfGVlI> NVrUUnF3OjV{Mki4NVU>
HEK293/hERG Mlq5SpVv[3Srb36gRZN{[Xl? MUSxNOKh|ryP NI\GZ|MyyqCq M2TudpJme3WudIOgbY4h[SC2aX3lMYRmeGWwZHXueEBz\WS3Y4Tpc44hdWG2dYLlJIhGWkdicILveIVqdsLi M3PrXVI2OjF6NE[5
RBE4 Mle2RZBweHSxc3nzJGF{e2G7 NIPjS2gzyqEQvF2= MmDwN-KBmzJ2wrDo NEjrfoZqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHTldIVv\GWwdHz5 M1vDNFI2OTJ6MEK1
RBE4 MWfGeY5kfGmxbjDBd5NigQ>? NV;mV41rOsLizszN NXHP[ZB6O+LCk{K0xsBp NHXwTHVqdmO{ZXHz[ZMhfGinIGjCVFEheHKxdHXpckBt\X[nbIOgZYZ1\XJiMzDhcoQhPsLiaDDv[kB1emWjdH3lcpQ> MXGyOVEzQDB{NR?=
RBE4 NEC1PIhHfW6ldHnvckBCe3OjeR?= MUKyxsDPxE1? Ml\KN-KBmzJ2wrDo M1yxT4lv[3KnYYPld{Bi[3SrdnWgZ4F{eGG|ZT2xNkBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7lduKh MnrhNlUyOjhyMkW=
RBE4 M3TqfmZ2dmO2aX;uJGF{e2G7 NHzBPFQzyqEQvF2= NFTQTFY{6oDVMkVCpIg> MoTDbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiUl;TJJRqdWVvZHXw[Y5l\W62bIm= NIK0SJEzPTF{OECyOS=>
RBE4 NXfGUIFQTnWwY4Tpc44hSXO|YYm= NWnQR|Y5OsLizszN MVSz5qCUOjUEoHi= MorQbY5lfWOnczDhJIRmdGG7ZXSg[IVxdGW2aX;uJI9nKHSqZTDFVkBE[TJtwrDjc451\W62IHH0JFbDqGhib3[gbY5kfWKjdHnvckB{cWewaX\pZ4FvfGy7 MV6yOVEzQDB{NR?=
RBE4 MlPySpVv[3Srb36gRZN{[Xl? MX2yxsDPxE1? M1zaPVPjiJN{NNMgbC=> NILzdGFqdmS3Y3XzJIFvKG:4ZYLsc4FlKG:oIFPhNkvDqGmwIITo[UBucXSxY3jvcoRzcWFiaX6geIhmKG[rcoP0JFbDqGhib3[gbY5kfWKjdHnvckApeOLCiU|ihKkxNjByMTmgZpV1KEOjMjxCpIxmfmWuczDpckB1cGm|IH;y[4Fv\WyuZTDk[YNz\WG|ZXSgZYZ1\XJiMUNCpIghd2ZiaX7jeYJifGmxbh?= M2LpdFI2OTJ6MEK1
Huh-7  NYLV[mVnTnWwY4Tpc44hSXO|YYm= MYex{txoN22O MmXUN-KBmzJ2wrDo MmrVbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCDUFWxJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy MlvjNlUxOjZzN{S=
HepG2  M{TaVmZ2dmO2aX;uJGF{e2G7 NUHw[I43Oc7:Zz;tUC=> MYqz5qCUOjUEoHi= MYDpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NVPCcINZOjVyMk[xO|Q>
H838-LKB1 Ml7XSpVv[3Srb36gRZN{[Xl? NGTxTYQ{OMLibnevcYw> NETpU2EyOi9zODDo NHL6e2lqdmO{ZXHz[ZMhfGinIIDyc5RmcW5ibHX2[Yx{KG:oIFLpVOKh M{TYclI2ODFzMEiy
H838-KDLKB1  NIXzbnRHfW6ldHnvckBCe3OjeR?= NGrpO2Q{OMLibnevcYw> M33wOFEzNzF6IHi= M1eyRYlv[3KnYYPld{B1cGVicILveIVqdiCuZY\lcJMhd2ZiQnnQxsA> MXOyOVAyOTB6Mh?=
H838-KDLKB1  MYPGeY5kfGmxbjDBd5NigQ>? M3nTR|MxyqCwZz;tcC=> NVTj[XI1OTJxMUigbC=> MXnpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyaH;zdIhwenmuYYTl[EBmUUZ{zsGgLJBpd3OyaH:t[WlHOs7zKR?= MWKyOVAyOTB6Mh?=
3T3-L1 NIXJVWhHfW6ldHnvckBCe3OjeR?= Mm\FOUDPxGdxbXy= NIj2e40{OCCvaX6= MXHtbY1q[3NidHjlJIVn\mWldIOgc4YhcW6|dXzpckBidmRiY3H1d4V{KHKxYoXzeEBxcG:|cHjvdplt[XSrb36gc4YhSWu2IDjT[ZIhPDd|KTDhcoQheGixc4Doc5J6dGG2aX;uJI9nKEGVMU[wJEhVcHJiNkSyJIFv\CCVZYKgOVg5MQ>? M{fPVFI1QDR|OEK3
3T3-L1 MmW0SpVv[3Srb36gRZN{[Xl? NIrFeFQ2KM7:Zz;tcC=> MWizNEBucW5? Mm\CdoVk[XCrdIXsZZRmeyCrboP1cIlvKGGldHnvckB4cXSqIILld5Bm[3RidH:gdoVofWyjdHnu[{BCc3RiYXP0bZZqfHliYX7kJGFUOTZyIIDoc5NxcG:{eXzheIlwdg>? MXiyOFg1Ozh{Nx?=
3T3-L1 MoDxSpVv[3Srb36gRZN{[Xl? MkS3OUDPxGdxbXy= NX\hZ3dbOzBibXnu MonGZ4F2e2W|IILleoVze2mkbHWgdoVlcXO2cnnieZRqd25ib3[gS2xWXDR? MV:yOFg1Ozh{Nx?=
3T3-L1 NFO4SIVHfW6ldHnvckBCe3OjeR?= Ml\WOUDPxGdxbXy= MoS5NeKhcA>? NEf6UIlk[XW|ZYOgdoVlcXO2cnnieZRqd25ib3[gS2xWXDRiYoX0JI5wfCCrbnPy[YF{\SCrbjDncJVkd3OnIIXweIFs\Q>? MVyyOFg1Ozh{Nx?=
3T3-L1 NIHLco9HfW6ldHnvckBCe3OjeR?= NUS1e3lFPSEQvHevcYw> MnPQNeKhcA>? NUPN[lZ7[2G3c3XzJJBpd3OyaH;yfYxifGmxbjDv[kB1cGViRn;4U|EhfHKjboPjdolxfGmxbjDmZYN1d3J? MmnzNlQ5PDN6Mke=
HeLa  MX7GeY5kfGmxbjDBd5NigQ>? MomwOUDPxGdxbXy= MkD3N{Bp MkDNZ4F2e2W|IH71Z4xm[XJiZYjjcJV{cW:wIH;mJJRp\SCIb4jPNUB1emGwc3PybZB1cW:wIH\hZ5RweiCjbnSg[IVkemWjc3XzJJRz[W6|Y4LpdJRqd25ib3[gSo95VzFvcnXneYxifGWmIHflcoV{ NVnab3hjOjR6NEO4Nlc>
HEK293 Mle4SpVv[3Srb36gRZN{[Xl? NYLzZVk4PcLizsznM41t MXGxNuKhcA>? NFHQXmNi[m:uaYPo[ZMhS02DLXnu[JVk\WRiQ2LFUGQzKHOnY4LleIlwdg>? NHfR[3kzPDZ6N{SzNS=>
COS-1 MX7GeY5kfGmxbjDBd5NigQ>? NWDifpByPSEEtXevcYw> NYr2OXNyOjRiaNMg M4TVNZJme3S{aXP0d{Btd2OjbHn6ZZRqd25ib3[gUmIhcW5idHjlJJBmemmwdXPs[YFzKHKnZ3nvcuKh MlHsNlQ3PzF5NUG=
PRP NEfyZoRHfW6ldHnvckBCe3OjeR?= M1;RU|ExKM7:TR?= MUPhZpJw\2G2ZYOgV2RHNTIQsT3t[YRq[XSnZDDDXGNTPyCneITldo5idGm8YYTpc47DqA>? NVjiRVJDOjR4Nki3OVA>
RAW264.7 M3jxV2Fxd3C2b4Ppd{BCe3OjeR?= M1jseFQh|ryP M1zWc|Q5KGh? NYn6SJJo[XS2ZX71ZZRmeyC2aHWgbY5pcWKrdHnvckBw\iCxeD3MSGwucW6mdXPl[EBieG:ydH;zbZMh[W6mIITo[UBn[WOrbHn0ZZRqd25ib3[gZ4hwdGW|dHXyc4wh\W[obIX4JIJ6KEGlLXjFMVE5SS2QSEK= NFzlRXUzPDZ|OUCzNi=>
MDMs NFfOZ2lCeG:ydH;zbZMhSXO|YYm= MWKxNQKBkc7:Zz;tcC=> NFrxOYQyOi9zNTDo NG\i[mpqdmS3Y3XzJIFxd3C2b4Ppdy=> Mn[1NlQ2PTZ4OUW=
PMHs  NH3Ke2VHfW6ldHnvckBCe3OjeR?= NV\OcGFTOTEkgKOyNQKBkc7:Zz;tcC=> MlzUNlTjiImq NXzuWWVITE2VTx?= MYDpcoR2[2WmIFXSJJN1emW|cx?= MWKyOFQxPzJ2Mh?=
PMHs  MUTBdI9xfG:|aYOgRZN{[Xl? NIrP[JIyOOLCk{Kw5qCK|rypL33s MoP0NlTjiImq NGC1elRFVVOR MlHibY5kemWjc3XzJINmdGxiZHXheIg> NVfDNXBwOjR2MEeyOFI>
HEK293/tau MUPGeY5kfGmxbjDBd5NigQ>? MXO1JO69VQ>? NF;Wbm8yNzJxNDDo Mne5bY5lfWOnczDHc4xocSCocnHncYVvfGG2aX;uxsA> NV3TelJ4OjR|NkiwPFk>
HEK293/tau NELxcYlHfW6ldHnvckBCe3OjeR?= M3;ic|Uh|ryP M2[zSVMhcA>? NELteHlqdmS3Y3XzJJRifSCqeYDldpBpd3OyaH;yfYxifGmxbh?= MX2yOFM3QDB6OR?=
ADF NUfCVWNSTnWwY4Tpc44hSXO|YYm= NWXzTZhvOTBizszN MUSxOkBp NUDHTHlxcW6qaXLpeJMhfGinIGruR4wzNWmwZIXj[YQhfHKjboPsc4NifGmxbjDv[kBEWlR? MUOyOFIzQDJ|Mh?=
U373  NGTiXpNHfW6ldHnvckBCe3OjeR?= NEfKO20yOCEQvF2= MmG3NVYhcA>? NE[5VIpqdmirYnn0d{B1cGViWn7DcFIucW6mdXPl[EB1emGwc3zvZ4F1cW:wIH;mJGNTXA>? Mnq2NlQzOjh{M{K=
RKO-HIPK2i NWHxcnlJTnWwY4Tpc44hSXO|YYm= MVmxNEDPxE1? M1LhTlE3KGh? MmT0bY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> MWKyOFIzQDJ|Mh?=
ADF  NW\lXWxmTnWwY4Tpc44hSXO|YYm= NHHuc5UyOCEQvF5CpC=> NV;seWp{PiCq NUDQV24ycW2yYXnyd{B1cGViRFOgZYN1cX[jdHnvci=> MlTSNlQzOjh{M{K=
Huh7 NEP6VWJHfW6ldHnvckBCe3OjeR?= NF:3W2o2KM7:Zz;tcC=> MWW0JIg> NEO1boli[m:uaYPo[ZMhfGinIIPlZ5JmfGmxbjDv[kAhcW62cnHj[YxtfWyjcjDBdI9D MkXINlQyODBzNEC=
Huh7 M2PqOGZ2dmO2aX;uJGF{e2G7 NVnKZVNIPSEQvHevcYw> M2LPOFEhcA>? NXG0eIJK[2G3c3XzJIEhe2mpbnnmbYNidnRiaX7jdoVie2ViaX6gRZBwSi2lcnXzZ4VvfHN? MY[yOFExODF2MB?=
Huh7 M3;MU2Z2dmO2aX;uJGF{e2G7 M{LR[|XjiJNzMNMgcocwdWx? NITRenUyOiCq NHruZYRqdmO{ZXHz[ZMhSXCxQj3jdoV{[2WwdIOge4l1cG:3dDDpcohq[mm2aX7nJJNm[3KndHnvci=> MoLpNlQyODBzNEC=
BAECs M1iwXWZ2dmO2aX;uJGF{e2G7 NW[xNXRmPSEQvHevcYw> MmDUNE01KGh? MmC0bY5lfWOnczD0bIUhemGyaXSg[IVxcG:|cHjvdplt[XSrb36gc4Yh\U6RUzDheEBU\XJzMUe5 NWHiWFRbOjRyOEWyNlU>
Macrophages NV7MR5JPTnWwY4Tpc44hSXO|YYm= M2PrcFcyKML3TR?= NGezTI83KGh? MYTpcohq[mm2czDseY5ie2mwIHnueIVzdmGuaYrheIlwdsLi MUeyOFA{QTd2MB?=
Colo 205 NFOzfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfMR4cxNTVizsznM41N MWW0PEBp NHznOZBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDzeZNx\W6|aX;uJIN2dHS3cnXzJJdqfGhiYX6g[ZN1cW2jdHXkJGlEPTBib3[gglE2KG6pL33M NUnSdJFNOjN7N{O5PVY>
Colo 205 NWXmXmJuTnWwY4Tpc44hSXO|YYm= MVewMlAyOi1yLkCyOUDPxGdxbVy= NY[3eodpOTRiZB?= MUDy[YR2[2W|IITo[UBkdG:wb3flcolkcXS7IH;mJGNwdG9iMkC1JGNUS3N? M1r2ZVI{QTd|OUm2
Colo 205 MnzMRZBweHSxc3nzJGF{e2G7 M2Wzd|AvOSEQvHevcWw> Mne1NE0zPCCq NV\OUYhTcW6mdXPld{BieG:ydH;zbZMhd2ZiQ3;sc{AzODViY3XscJMhcW5ic4XzdIVve2mxbjDjeYx1fXKncx?= NIr3To8zOzl5M{m5Oi=>
Colo 205 MYPGeY5kfGmxbjDBd5NigQ>? NIfY[WkxNjBzNTFOwIcwdUx? M1;VWVI1KGh? NUDPRVJ{cW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBGWiC|dILld5MuemWuYYTl[EBo\W6ncx?= NV7JcIR2OjN7N{O5PVY>
Colo 205 NHv0THNHfW6ldHnvckBCe3OjeR?= M1\TfFAvODF3IN88[{9uVA>? MVOyOEBp M1[5WolvcGmkaYTzJJRp\SCjY4Tpeol1gSCxZjDNUXB{ NH\6R3AzOzl5M{m5Oi=>
IBRS2 NFzJUoFHfW6ldHnvckBCe3OjeR?= NWHMZmFIPSEQvHevcYw> MYmwMlUhcA>? M4jwW2ROW09? MoDy[Il{enWydIOgeIhmKEWUR1nDJIFv\CCJb3znbeKh MWeyN|k3OzV|NB?=
IBRS2 NWrEUVhuTnWwY4Tpc44hSXO|YYm= MVK1JO69\y:vbB?= MWOwMlUhcA>? M2HRbmROW09? MUDlcohidmOnczDGUWRXKGmwZnXjeIlwdg>? NHnJVIszOzl4M{WzOC=>
HeLa NWDZcXBoTnWwY4Tpc44hSXO|YYm= NUjtbJJuOiEQvF2= NVyxcIRNOiCqwrC= M4DmTIF1fGWwdXH0[ZMhfGinIGTOSk1qdmS3Y3XkJJNm[3KndHnvckBw\iCLTD2xOS=> MVSyN|k2ODh7Mh?=
HFS  MnXESpVv[3Srb36gRZN{[Xl? NHnsdlQxNTFizsznM41t M4rQTlI1KGh? MmDzS2xVWCCneIDy[ZN{cW:wIILlZYNp\XNiYTDwcIF1\WG3IHH0JINwdmOnboTyZZRqd26|IHHzJIxwfyCjczCwMlAyKML3Zz;tcC=> NUHDR|dxOjN6OUS2N|M>
HFS  MWjGeY5kfGmxbjDBd5NigQ>? NVzDdIRiOC5yMTFCuYcwdWx? M3\ldVI1KGh? M2LWVYlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBodHmlb4PwbIlv\2:uaYDp[EB{gW62aHHz[UBo\W6nczDheEA3KGh? M2LyZVI{QDl2NkOz
OVCAR-3 MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyx5qCUOTYEoN88UeKh MVSyOOKhcA>? NFftSGhqdmS3Y3XzJIEhdG:|czDv[kBk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7wrC= MVyyN|gzPjl4NB?=
OVCAR-3 MUnGeY5kfGmxbjDBd5NigQ>? MYSx5qCUOTYEoN88UeKh NX3We2t1OjUEoHi= M2nIc4lv\HWlZYOgcpVkdGWjcjDkZY1i\2V? MnuyNlM5OjZ7NkS=
OVCAR-3 MnHQRZBweHSxc3nzJGF{e2G7 M3qzU|EuOTEEoN88US=> NFruWGY1KGh? MnWybY5lfWOnczD0bIUh[WO2aY\heIlwdiCxZjDhdI9xfG:|aYOtdoVt[XSnZDDwdo91\Wmwcx?= NIXzb5MzOzh{Nkm2OC=>
OVCAR-3 M3frS2Fxd3C2b4Ppd{BCe3OjeR?= M3LaUFExyqEQvF2= M{TpU|I1yqCq M{LvPIlv\HWlZYOgZYN1cX[jdHnvckBw\iClYYPwZZNmew>? MV6yN|gzPjl4NB?=
OVCAR-3 M2r3R2Z2dmO2aX;uJGF{e2G7 NVLGW3RzOeLCk{GwxsDPxE1? M1vWblI1yqCq MlPlbY5lfWOnczDkbZNzfXC2aX;uJI9nKHSqZTDtbZRw[2ixbnTybYFtKHS{YX7zcYVu[nKjbnWgdI91\W62aXHs NYXVTIxZOjN6Mk[5OlQ>
OVCAR-3 M4TLOWZ2dmO2aX;uJGF{e2G7 NILKO4sy6oDVMUFCpO69VQ>? MnPUNlTDqGh? MkmwbY5lfWOnczDmc5Ju[XSrb36gc4YhemWjY4TpeoUhd3i7Z3XuJJNx\WOrZYO= NHfDNIozOzh{Nkm2OC=>
OVCAR-3 MonoSpVv[3Srb36gRZN{[Xl? M4[ydFHjiJNzMNMg{txO MUKyOOKhcA>? MknFbY5pcWKrdIOgZ4VtdCCjZHjld4lwdiCjbnSgcYloemG2aX;u NGT1d|gzOzh{Nkm2OC=>
MKN45 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjuTWM2ODxyLkCwNUDPxGdxbXy= NGLsRoUzOzd7M{O0Ni=>
LOVO M1;pfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMUKg{txoN22u M2XET|I{Pzl|M{Sy
A549 NIm1PVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf0[IpVUUN3ME2wMlA1KM7:Zz;tcC=> MoXFNlM4QTN|NEK=
MDA-MB-435 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3jWZI2UUN3MEywMlAxOSEQvHevcYw> MW[yN|c6OzN2Mh?=
HepG2 MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf1TWM2ODxyLkCwNUDPxGdxbXy= NWrncJZsOjN5OUOzOFI>
HL-60 NXzOTIlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zGcGlEPTB:MD6wNFEh|rypL33s MkLiNlM4QTN|NEK=

... Click to View More Cell Line Experimental Data

Protocol

Cell Research
+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method: HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water <1 mg/mL
Ethanol <1 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID